- Neuroscientific Biopharmaceuticals (NSB) has appointed two new members to the board to support upcoming clinical programs in glaucoma and neurodegenerative diseases
- The company is focussed on developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions
- Dougal Thring has been appointed Vice President of Clinical Development, while Dr Alexndra Heaton will take the role of Director of Operations
- Neuroscientific Biopharmaceuticals is up 5.66 per cent, trading at 28 cents
Neuroscientific Biopharmaceuticals (NSB) has appointed two new members to the board to support upcoming clinical programs in glaucoma and neurodegenerative diseases.
The company is focussed on developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions.
Dougal Thring has been appointed Vice President of Clinical Development, while Dr Alexndra Heaton will take the role of Director of Operations.
Dougal Thring comes with over 12 years of experience in leading all aspects of clinical development of clinical studies for numerous biotechnology companies.
Prior to joining Neuroscientific Biopharmaceuticals, Dougal worked as a Head of Clinical Solutions at Australian contract reach organisation Linear Clinical Research.
Dr Alexandra Heaton has previously held the role of U.S. Client Engagement with Linear Clinical Research and holds a PhD in Neuroscience, with her research work focussed on anti-oxidative, anti-inflammatory and anti-apoptotic effects of dietary supplementation in the brain in addition to enhancing neuroplasticity, synaptogenesis and neural signalling.
“NeuroScientific is pleased to have secured both Dougal and Alexandra in key executive management positions at an important stage of development in the company’s research and development program,” said CEO and Managing Director of NSB, Matthew Liddelow.
Neuroscientific Biopharmaceuticals is up 5.66 per cent, trading at 28 cents at 2:00 pm AEDT.